Bank of New York Mellon Corp Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)

Bank of New York Mellon Corp purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 51,445 shares of the company's stock, valued at approximately $792,000. Bank of New York Mellon Corp owned about 0.36% of Inhibrx as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. New York State Common Retirement Fund purchased a new position in shares of Inhibrx during the fourth quarter worth approximately $53,000. Rhumbline Advisers acquired a new stake in Inhibrx during the 4th quarter worth $228,000. China Universal Asset Management Co. Ltd. purchased a new position in Inhibrx during the 4th quarter worth $47,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Inhibrx in the fourth quarter valued at $348,000. Finally, Exchange Traded Concepts LLC purchased a new stake in shares of Inhibrx in the fourth quarter valued at about $148,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Stock Down 1.4 %

Inhibrx stock traded down $0.20 during mid-day trading on Friday, reaching $14.12. 122,051 shares of the company were exchanged, compared to its average volume of 218,202. The firm's 50-day simple moving average is $13.36 and its two-hundred day simple moving average is $14.60. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $35.42.

Remove Ads

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. As a group, research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.